Repligen corp stock.

The current consensus among 14 polled investment analysts is to buy stock in Repligen Corp. This rating has held steady since August, indicating a consistent belief in the company’s potential for growth. Repligen Corp has reported strong financials for the current quarter, with earnings per share of $0.55 and sales of $179.5 million.Repligen Corp . Repligen Corp RGEN . $ 68.86 . $1.83 2.73% 15%. ... Repligen stock is the IBD Stock Of The Day after the medical technology company "shot the lights out" in the first quarter, ...The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …Repligen Corporation share price live 164.94, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Repligen Corporation real time stock price chart below. You can ...Nov 24, 2023 · In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.

Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.Saint Barbara is the patron saint of Marine artillerymen. She is also recognized by Marine Corps Aviation ordnancemen. Saint Michael is the patron saint of the armed forces.Dec 4, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.

Nov 9, 2023 · Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.

As President and CEO at REPLIGEN CORP , Tony J. Hunt made $7,713,930 in total compensation. Of this total $800,000 was received as a salary, $785,440 was received as a bonus, $1,623,698 was received in stock options, $4,499,792 was awarded as stock and $5,000 came from other types of compensation. This information is according to proxy ...

Repligen Corp., the recipient of this investment, is a global life sciences company specializing in providing bioprocessing technologies and solutions used in manufacturing biological drugs. ... While Repligen’s stock opened at $156.63 on Friday, the company had a market capitalization of $8.72 billion, with a beta of 1.08, and PE ratio of …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Estimate Revisions Score of 38. Comparing Avantor Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.CI. Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08:00 AM. Nov. 15. CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07.

Nov 23, 2023 · The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN ... Feb 22, 2023 · Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ... Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...The Growth Grade Winner: Repligen Corp. As you can clearly see from the Growth Grade breakdown above, Repligen Corp has a more attractive growth grade than Medtronic PLC. For investors who focus solely on how a company is growing relative to other companies in the same industry, Repligen Corp could be a good stock to add to their portfolio.

11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price.

Repligen Corp. - RGEN STOCK NEWS . IMPACT. SENTIMENT. 11/14/2023 02:01 PM. RGEN: Nasdaq ... Repligen Corp. Nasdaq:RGEN. RGEN Rankings #1033 Ranked by Market Cap #4078 Ranked by Stock Gains. N/A Ranked by Dividends. RGEN Stock Data. Industry Biological Product (except Diagnostic) Manufacturing .Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Stock analysis for Repligen Corp (R2GE34:B3 Day) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts …

However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ...

Within the last quarter, Repligen (NASDAQ:RGEN) has observed the following analyst ratings: According to 7 analyst offering 12-month price targets in the last …

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. Stock analysis for Repligen Corp (RGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.When you start a small business, you’ll have many decisions to make. The process involves everything from choosing a business model and designing your marketing materials to hiring employees and setting prices.View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, ...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. WALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and …Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …Instagram:https://instagram. aftermarket screenercrnx stockcaravana car salesdr phillip frost Nov 13, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. islamic forex accountsqid etf Repligen Corp (RGEN) Stock Shows Positive Performance and Promising Price Forecasts in the Biopharmaceutical Industry. On November 2, 2023, Repligen Corp (RGEN) experienced positive stock performance, with analysts forecasting a potential increase in its stock price. According to data from CNN Money, there are 13 analysts … oil refineries in us What is Repligen Corp (RGEN)'s stock price today? The current price of RGEN is $153.28. The 52 week high of RGEN is $212.17 and 52 week low is $110.45. When is next earnings date of Repligen Corp (RGEN)? The next earnings date of Repligen Corp (RGEN) is …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.